| Lupus Nephritis |
FACT, NCT05546047: A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients |
|
|
| Active, not recruiting | 4 | 34 | US | Acthar Gel 80 UNT/ML Injectable Solution, Tacrolimus 1.0 mg | NephroNet, Inc., Mallinckrodt | Fibrillary Glomerulonephritis | 10/23 | 10/24 | | |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
2020-005835-60: Treatment of lupus nephropathy without the addition of oral corticosteroids: a study comparing conventional corticosteroid and Mycophenolate Mofetil (MMF) therapy with Obinutuzumab and MMF Traitement des néphropathies lupiques sans adjonction de corticoïdes par voie orale: étude comparant un traitement classique par corticoïdes et Mycophénolate Mofétil (MMF) à un traitement par l’Obinutuzumab et le MMF |
|
|
| Not yet recruiting | 3 | 196 | Europe | Obinutuzumab, PREDNISONE, Mycophenolate mofetil, Azathioprine, RO5072759, Concentrate for solution for infusion, Tablet, , Gazyvaro | Assistance Publique – Hôpitaux de Paris (AP-HP), ministère de la santé, Roche | The study population will consist of Children (14 years and above) and adults (until 75 years old) with lupus nephritis ISN/RPS class III or IV (A or A/C) ± V with active lesions in at least 10% of the viable glomeruli, AND urine protein-to-creatinine ratio (uPCR) ≥ 0.5 g/g. La population étudiée sera composée d'enfants (à partir de 14 ans) et d'adultes (jusqu'à 75 ans) présentant un lupus néphrétique ISN/RPS de classe III ou IV (A ou A/C) ± V avec des lésions actives dans au moins 10 % des glomérules viables, ET un rapport protéines/créatinine urinaire (uPCR) ≥ 0,5 g/g., Children (14 years and above) and adults (until 75 years old) with lupus nephritis Enfants (à partir de 14 ans) et adultes (jusqu'à 75 ans) atteints de lupus néphrétique, Body processes [G] - Immune system processes [G12] | | | | |
2020-003767-25: A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplan administered subcutaneously in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis |
|
|
| Ongoing | 3 | 100 | Europe, RoW | Pegcetacoplan, APL-2, Solution for injection/infusion | Apellis Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc. | complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN), Rare kidney disease which can reoccur after a kidney transplant., Diseases [C] - Immune System Diseases [C20] | | | | |
2020-005830-14: Study of safety, efficacy and tolerability of ianalumab versus placebo, in combination with SOC therapy, in participants with active lupus nephritis Randomizált, kettős vak, párhuzamos csoportos, placebo kontrollos,multicentrikus, III. fázisú vizsgálat a hagyományos kezelés mellett alkalmazott ianalumab hatásosságának, biztonságosságának és tolerálhatóságának értékelésére aktív lupus nephritisben szenvedő résztvevők körében (SIRIUS-LN) |
|
|
| Ongoing | 3 | 420 | Europe, RoW | ianalumab, VAY736, Solution for injection in pre-filled syringe | Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG | Lupus nephritis, Inflammation of the kidneys that is a severe complication of systemic lupus, Diseases [C] - Immune System Diseases [C20] | | | | |
2021-005772-19: An extension clinical trial of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability in patients with active lupus nephritis Un estudio de extensión de secukinumab subcutáneo para evaluar la eficacia, seguridad y tolerabilidad a largo plazo en pacientes con nefritis lúpica activa. |
|
|
| Ongoing | 3 | 310 | Europe, RoW | Solution for injection in pre-filled syringe, Cosentyx | Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG | Lupus Nephritis Nefritis lúpica, Lupus Nephritis is an inflammation of kidneys caused by systemic lupuserythematosus, an autoimmune disease (body's immune system targetsits own body tissues) that can affect any part of the body. Nefritis lúpica:inflamación de los riñones causada por lupus eritematoso sistémico,enfermedad autoinmune (el sistema inmune ataca a los tejidos propios) que puede afectar a cualquier parte del cuerpo, Diseases [C] - Immune System Diseases [C20] | | | | |
2022-000257-83: A large global research study for an investigational drug called atacicept is being tested for the treatment of active lupus nephritis in a randomized manner, and is a placebo-controlled, double-blind study. Placebo-controlled provides a way to measure the actual effect of the investigational drug (atacicept). Double-blind means that the patient and the study doctor will not know if the patient is getting atacicept or placebo. |
|
|
| Not yet recruiting | 3 | 290 | Europe | Atacicept, VT-001, Solution for injection in pre-filled syringe | Vera Therapeutics, Inc., Vera Therapeutics, Inc. | patients with lupus nephritis sujetos con nefritis lúpica, Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus (SLE). SLE is an autoimmune disease; a disorder in which the body's immune system attacks the body's own cells and organs., Body processes [G] - Immune system processes [G12] | | | | |
2022-002833-33: A study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Un estudio para evaluar la seguridad y la eficacia a largo plazo de pegcetacoplán en participantes con glomerulopatía C3 o glomerulonefritis membranoproliferativa por inmunocomplejos |
|
|
| Ongoing | 3 | 100 | Europe, RoW | Pegcetacoplan, APL-2, Solution for injection/infusion, Aspaveli | Apellis Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc | C3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN) Glomerulopatía por C3 (GC3) o glomerulonefritis membranoproliferativa por inmunocomplejos (GNMP-IC), Rare kidney disease which can reoccur after a kidney transplant. Enfermedad renal rara que puede reaparecer después de un trasplante de rinón, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT05232864 / 2021-005772-19: Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis |
|
|
| Terminated | 3 | 31 | Europe, Japan, RoW | Secukinumab, AIN457 | Novartis Pharmaceuticals, Novartis Pharma AG | Lupus Nephritis | 08/23 | 08/23 | | |
| Terminated | 3 | 275 | Europe, Canada, Japan, US, RoW | secukinumab, AIN457 | Novartis Pharmaceuticals | Lupus Nephritis | 09/23 | 09/23 | | |
NCT06406205: A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis |
|
|
| Recruiting | 3 | 270 | RoW | Voclosporin（QL1074）, Placebo | Qilu Pharmaceutical Co., Ltd. | Lupus Nephritis | 06/27 | 06/28 | | |
VALIANT, NCT05067127: Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis |
|
|
| Active, not recruiting | 3 | 90 | Europe, Canada, Japan, US, RoW | Pegcetacoplan, Placebo | Apellis Pharmaceuticals, Inc. | C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | 06/24 | 12/24 | | |
| Active, not recruiting | 3 | 252 | Europe, US, RoW | Obinutuzumab, Gazyva, GA101, RO5072759, MMF, Prednisone, Placebo, Methylprednisolone, Acetaminophen, Diphenhydramine | Hoffmann-La Roche | Lupus Nephritis | 08/24 | 02/29 | | |
|
| Recruiting | 3 | 183 | Europe, Canada, Japan, US, RoW | LNP023, iptacopan | Novartis Pharmaceuticals, Novartis Pharma AG | C3 Glomerulopathy, Idiopathic Immune-complex-membranoproliferative Glomerulonephritis | 10/24 | 12/28 | | |
| Recruiting | 3 | 40 | US | Voclosporin, Placebo Oral Capsule | Aurinia Pharmaceuticals Inc., Aurinia Pharmaceuticals Inc. | Adolescent Lupus Nephritis | 12/24 | 01/25 | | |
| Suspended | 3 | 360 | Europe, US | Atacicept, VT-001, Placebo | Vera Therapeutics, Inc. | Lupus Nephritis (LN) | 03/26 | 12/28 | | |
| Enrolling by invitation | 3 | 40 | NA | voclosporin | Aurinia Pharmaceuticals Inc., Labcorp Corporation of America Holdings, Inc | Adolescent Lupus Nephritis | 06/26 | 09/26 | | |
| Recruiting | 3 | 68 | Europe, Canada, Japan, US, RoW | Placebo, iptacopan | Novartis Pharmaceuticals | IC-MPGN | 10/26 | 11/26 | | |
| Recruiting | 3 | 346 | Europe, Japan, US, RoW | Anifrolumab, Medi-546, Placebo | AstraZeneca | Lupus Nephritis | 09/26 | 07/28 | | |
| Recruiting | 3 | 420 | Europe, Canada, US, RoW | ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo | Novartis Pharmaceuticals | Lupus Nephritis | 03/27 | 07/30 | | |
VALE, NCT05809531 / 2022-002833-33: An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis |
|
|
| Active, not recruiting | 3 | 100 | Europe, US, RoW | Pegcetacoplan, APL-2 | Apellis Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc | C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | 07/27 | 07/27 | | |
OBILUP, NCT04702256 / 2020-005835-60: Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF |
|
|
| Recruiting | 3 | 196 | Europe | Obinutuzumab administration, GAZYVARO® administration, Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil, Corticosteroid Series, Administration of methylprednisolone, paracetamol and dexchlorpheniramine, Premedication | Assistance Publique - Hôpitaux de Paris, Roche Pharma AG | Lupus Nephritis, Systemic Lupus Erythematosus (SLE) | 12/31 | 12/31 | | |
NCT04892212: Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis |
|
|
| Not yet recruiting | 2/3 | 20 | NA | Sirolimus, Rapamycin | Peking Union Medical College Hospital, North China Pharmaceutical Group Corporation | Lupus Nephritis, Immunosuppression, Effect of Drug | 06/23 | 10/23 | | |
| Completed | 2 | 126 | Europe, US, RoW | Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Gazyva, GA101, RO5072759, Placebo, Methylprednisolone, Prednisone | Hoffmann-La Roche | Lupus Nephritis | 01/19 | 08/23 | | |
|
|
|
|
NCT03453619: Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies |
|
|
| Completed | 2 | 21 | US | APL-2 | Apellis Pharmaceuticals, Inc. | IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease | 04/20 | 08/23 | | |
2020-001537-13: Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) |
|
|
| Not yet recruiting | 2 | 120 | Europe | Ravulizumab, ALXN1210, Concentrate for solution for infusion, Ultomiris | Alexion Pharmaceuticals, Inc., ALEXION PHARMACEUTICALS INCORPORATED, Alexion Pharmaceuticals, Inc. | Lupus Nephritis (LN)Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN)Immunoglobulin A Nephropathy (IgAN), Diseases [C] - Immune System Diseases [C20] | | | | |
2021-000097-29: A Phase II Randomized Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients with Active Class III or IV Lupus Nephritis Estudio fase II, aleatorizado y controlado paraevaluar la eficacia, seguridad y farmacocinética de obinutuzumab en pacientes adolescentes con nefritis lúpica de casle III o IV activa |
|
|
| Not yet recruiting | 2 | 30 | Europe | Obinutuzumab, mycophenolate mofetil, RO5072759, Concentrate for solution for infusion, Tablet, Gazyvaro, Myfenax | Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. Hoffman-La Roche Ltd., F. HOFFMANN - LA ROCHE LTD., F. Hoffman-La Roche Ltd. | Lupus Nephritis (LN) Nefritis lúpica (NL), Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). SLE is an autoimmune disease, in which the body’s immune system attacks its own healthy body tissue. La nefritis lúpica es una inflamación del riñón causada por el lupus eritematoso sistémico(LES).LES es una enfermedad autoinmune,en la que el sistema inmune del cuerpo ataca sus propios tejidos sanos, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04835883: Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients |
|
|
| Recruiting | 2 | 10 | RoW | CS20AT04 (allogenic bone marrow derived mesenchymal stem cell) | Hanyang University Seoul Hospital, Corestem, Inc., Ministry of Health & Welfare, Korea | Systemic Lupus Erythematosus | 11/21 | 01/26 | | |
2020-005568-79: A Clinical Study of Nipocalimab in Adult Participants with Active Lupus Nephritis |
|
|
| Not yet recruiting | 2 | 80 | Europe | Nipocalimab, JNJ-80202135, Solution for infusion | Janssen-Cilag International NV, Janssen Research & Development, LLC | Active Lupus Nephritis, Lupus Nephritis, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04924296: A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis |
|
|
| Not yet recruiting | 2 | 60 | NA | SHR-1314, Placebo | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Lupus Nephritis | 12/21 | 09/22 | | |
| Terminated | 2 | 31 | Europe, Canada, RoW | Placebo, Cemdisiran, ALN-CC5 | Alnylam Pharmaceuticals | IgA Nephropathy (IgAN), Berger Disease, Glomerulonephritis, IgA | 03/22 | 06/23 | | |
2021-002046-33: Study of efficacy and safety of LNP023 in participants with active lupus nephritis Class III-IV, +/- V Az LNP023 hatásosságának és biztonságosságának vizsgálata III-IV-es, +/- V-ös osztályú, aktív lupus nephritisben szenvedő résztvevők körében |
|
|
| Ongoing | 2 | 240 | Europe | Iptacopan, Prednisone, LNP023, Capsule, hard, Capsule, hard + tablet, Prednisone | Novartis Pharma AG, Novartis Farmacéutica S.A., Novartis Pharma AG | Lupus Nephritis Class III-IV, +/- V, Autoimmune disease, Diseases [C] - Immune System Diseases [C20] | | | | |
| Active, not recruiting | 2 | 13 | Europe, US, RoW | Pegcetacoplan | Apellis Pharmaceuticals, Inc. | C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis | 02/23 | 01/26 | | |
2018-003155-38: A Study of the Efficacy and Safety of Guselkumab in Participants with Active Lupus Nephritis |
|
|
| Not yet recruiting | 2 | 60 | Europe | Guselkumab, CNTO1959, Solution for injection in pre-filled syringe, TREMFYA | Janssen-Cilag International NV, Janssen Research & Development | Active Lupus Nephritis, Active Lupus Nephritis, Diseases [C] - Immune System Diseases [C20] | | | | |
| Terminated | 2 | 33 | Europe, US, RoW | Guselkumab Dose 1, CNTO 1959, Placebo, Guselkumab Dose 2, CNTO1959, Standard-of-care treatment | Janssen Research & Development, LLC | Lupus Nephritis | 02/23 | 02/23 | | |
| Completed | 2 | 57 | Europe, RoW | CFZ533, Placebo | Novartis Pharmaceuticals | Lupus Nephritis | 06/23 | 06/23 | | |
|
| Recruiting | 2 | 70 | Europe, US, RoW | ALXN2050, ACH-0145228 (formerly), Placebo | Alexion Pharmaceuticals, Inc. | Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN | 06/26 | 06/26 | | |
| Completed | 2 | 24 | Europe, RoW | MOR202 | HI-Bio | Glomerulonephritis, Membranous Nephropathy, antiPLA2R Positive | 12/23 | 12/23 | | |
| Completed | 2 | 177 | RoW | Zanubrutinib, BGB-3111, Brukinsa, Placebo | BeiGene | Lupus Nephritis | 02/24 | 08/24 | | |
NCT06209736: Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN |
|
|
| Recruiting | 2 | 20 | Europe, RoW | OMS906 study drug, OMS906 | Omeros Corporation | C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis | 01/25 | 04/26 | | |
SANCTUARY, NCT04564339: Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US, RoW | Ravulizumab, Ultomiris, Placebo, Background Therapy | Alexion Pharmaceuticals, Inc. | Lupus Nephritis, Immunoglobulin A Nephropathy | 04/25 | 05/26 | | |
ADX-097-201, NCT06419205: A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G |
|
|
| Not yet recruiting | 2 | 30 | NA | ADX-097 | Q32 Bio Inc. | IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy | 12/25 | 12/25 | | |
| Recruiting | 2 | 20 | Europe | Mesenchymal stem cells (MSC), MSV, GMP-compliant MSC manufactured by IBGM in Valladolid, Placebo, Saline solution | Red de Terapia Celular, Hospital del Río Hortega, Hospital Clínico Universitario de Valladolid, University of Valladolid, Citospin | Lupus Nephritis, Lupus Erythematosus | 07/25 | 07/26 | | |
NCT05810948: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) |
|
|
| Recruiting | 2 | 60 | RoW | efgartigimod IV, Placebo | argenx, Zai Lab (Shanghai) Co., Ltd. | Lupus Nephritis | 08/24 | 10/24 | | |
RESULT, NCT06500702: A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease |
|
|
| Not yet recruiting | 2 | 84 | NA | frexalimab, SAR442970, rilzabrutinib, placebo | Sanofi | Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion | 12/26 | 02/28 | | |
NCT06581198: A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN) |
|
|
| Recruiting | 2 | 144 | US, RoW | rapcabtagene autoleucel Regimen 1, rapcabtagene autoleucel Regimen 2, Standard of Care | Novartis Pharmaceuticals | Lupus Erythematosus, Systemic, Lupus Nephritis | 05/29 | 05/30 | | |
| Recruiting | 2 | 240 | Europe, US, RoW | Iptacopan (part 1), LNP023, Iptacopan (part 2), Placebo + standard of care, Iptacopan + placebo, LNP023 and placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Lupus Nephritis | 10/24 | 03/28 | | |
| Recruiting | 2 | 120 | RoW | Telitacicept 240 mg, RC18 240 mg, Telitacicept 160 mg, RC18 160 mg, Placebo | RemeGen Co., Ltd. | Lupus Nephritis | 12/25 | 01/26 | | |
SPARTAN, NCT04663204: A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy |
|
|
| Active, not recruiting | 2 | 12 | Europe | Sparsentan, RE-021 | University of Leicester, Travere Therapeutics, Inc. | Immunoglobulin A Nephropathy, Kidney Diseases, Glomerulonephritis, IGA, Glomerulonephritis, Autoimmune Diseases, Immune System Diseases | 03/25 | 03/25 | | |
| Recruiting | 2 | 105 | US | Mycophenolate Mofetil, MMF dosed per body surface area, MMF dosed phrmacokinetically | Children's Hospital Medical Center, Cincinnati, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Genentech, Inc. | Lupus Nephritis | 07/25 | 03/26 | | |
| Terminated | 2 | 19 | Europe, US, RoW | Daxdilimab, Placebo (Normal Saline) | Amgen, Horizon Therapeutics Ireland DAC | Lupus Nephritis | 01/24 | 01/24 | | |
NCT05517980: Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis |
|
|
| Not yet recruiting | 2 | 52 | NA | KP104 | Kira Pharmacenticals (US), LLC. | Glomerulonephritis | 09/25 | 09/25 | | |
| Recruiting | 2 | 80 | Europe, RoW | ALE.F02, Rituximab, GlucoCorticoid, Cyclophosphamid, Placebo, Immunosuppressive Agents | Alentis Therapeutics AG | Glomerulonephritis Rapidly Progressive | 09/25 | 09/25 | | |
NCT06058078: RY_SW01 Cell Injection Therapy in Active Lupus Nephritis |
|
|
| Recruiting | 2 | 60 | RoW | RY_SW01 cell injection, UC-MSC treatment, Basic treatment, Immunosuppressive drugs | Jiangsu Renocell Biotech Company, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Lupus Nephritis | 12/25 | 12/28 | | |
POSTERITY, NCT05039619 / 2021-000097-29: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants |
|
|
| Recruiting | 2 | 40 | Europe, Canada, US, RoW | Obinutuzumab, Gazyva, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone | Hoffmann-La Roche, Genentech, Inc. | Lupus Nephritis | 03/26 | 03/29 | | |
| Recruiting | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| Not yet recruiting | 2 | 80 | US | Placebo, Nipocalimab, JNJ-80202135, M281, Standard-of-care treatment | Janssen Research & Development, LLC, Janssen Research & Development, LLC | Lupus Nephritis | 02/28 | 02/28 | | |
KYSA-3, NCT06342960: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis |
|
|
| Recruiting | 1/2 | 32 | Europe | KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen, Cyclophosphamide, Fludarabine | Kyverna Therapeutics | Lupus Nephritis, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | 10/28 | 01/29 | | |
2022-001796-14: An open-label study to assess safety, efficacy and cellular kinetics of YTB323 in severe, refractory systemic lupus erythematosus (srSLE). |
|
|
| Not yet recruiting | 1/2 | 12 | Europe | YTB323, Dispersion for infusion | Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG | Systemic Lupus ErythematosusLupus Nephritis, Systemic Lupus ErythematosusLupus Nephritis, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT06153095: A Study of IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 1/2 | 30 | US, RoW | IMPT-514 | ImmPACT Bio | Systemic Lupus Erythematosus, Lupus Nephritis | 02/27 | 02/27 | | |
NCT05938725: KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis |
|
|
| Recruiting | 1/2 | 32 | US | KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen, Cyclophosphamide, Fludarabine | Kyverna Therapeutics | Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV | 08/25 | 08/26 | | |
| Recruiting | 1/2 | 56 | US, RoW | povetacicept, ALPN-303 | Alpine Immune Sciences, Inc. | Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 01/26 | 01/26 | | |
NCT05798117: An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1/2 | 24 | Europe, US, RoW | YTB323 | Novartis Pharmaceuticals | Systemic Lupus Erythematosus, Lupus Nephritis | 10/26 | 10/26 | | |
RESET-SLE, NCT06121297: a Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Systemic Lupus Erythematosus |
|
|
| Recruiting | 1/2 | 12 | US | CABA-201 | Cabaletta Bio | Systemic Lupus Erythematosus, Lupus Nephritis | 12/27 | 12/27 | | |
NCT04342325: The Clinical Trial of ADR-001 for IgA Nephropathy |
|
|
| Completed | 1 | 9 | Japan | infusion of ADR-001 (Mesenchymal stem cell) | Nagoya University, Rohto Pharmaceutical Co., Ltd. | Glomerulonephritis , IGA | 11/22 | 03/23 | | |
NCT05505955: Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency |
|
|
| Recruiting | 1 | 98 | RoW | HRS-5965, Placebo | Chengdu Suncadia Medicine Co., Ltd. | Glomerulonephritis | 04/23 | 04/23 | | |
NCT05780515: A Study of ANX009 in Adult Participants With Lupus Nephritis |
|
|
| Completed | 1 | 7 | RoW | ANX009, Recombinant humanized immunoglobulin G1 (IgG1) Fab | Annexon, Inc. | Lupus Nephritis | 08/23 | 10/23 | | |
EQUALISE, NCT04128579: Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis |
|
|
| Completed | 1 | 55 | Europe, US, RoW | Itolizumab [Bmab 600], Bmab600, Itolizumab | Equillium, Biocon Limited | Lupus Erythematosus, Lupus Nephritis | 11/23 | 01/24 | | |
|
|
|
|
|
AB-101-03, NCT06265220: AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 51 | US | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab | Artiva Biotherapeutics, Inc. | Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus | 10/26 | 10/26 | | |
NCT06497361: Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease |
|
|
| Recruiting | 1 | 30 | RoW | PRG-2311 | Tongji Hospital, Shenzhen Pregene Biopharma Co., Ltd. | Lupus Nephritis, IgG4-related Disease | 07/27 | 07/28 | | |
NCT06497387: Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease |
|
|
| Recruiting | 1 | 30 | RoW | PRG-1801 | Tongji Hospital, Shenzhen Pregene Biopharma Co., Ltd. | Lupus Nephritis, IgG4-related Disease | 07/27 | 07/28 | | |
| Recruiting | 1 | 30 | US | CNTY-101, IL-2, Lymphodepleting Chemotherapy | Century Therapeutics, Inc. | Systemic Lupus Erythematosus, Lupus Nephritis | 08/28 | 08/28 | | |
NCT06544330: Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With Severe, Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 42 | US | SYNCAR-001, STK-009 | Synthekine | Systemic Lupus Erythematosus, Lupus Nephritis | 04/28 | 04/41 | | |
NCT06377228: A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) |
|
|
| Not yet recruiting | 1 | 20 | NA | TAK-007, Chemotherapy Agents | Takeda | Refractory Lupus Nephritis | 04/29 | 04/29 | | |
ATA3219-AEC-104, NCT06429800: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants with Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 1 | 52 | NA | ATA3219 | Atara Biotherapeutics | Lupus Nephritis, Systemic Lupus Erythematosus | 10/27 | 04/29 | | |
NCT05085418: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Immune Nephritis, Autoimmune Diseases, Lupus Nephritis | 11/24 | 11/24 | | |
NCT06064929: A Study of Felzartamab in Participants With Lupus Nephritis |
|
|
| Recruiting | 1 | 20 | Canada, US, RoW | Felzartamab, HIB202 | HI-Bio | Lupus Nephritis | 06/26 | 06/26 | | |
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy |
|
|
| Active, not recruiting | 1 | 16 | Europe, Japan, US, RoW | Mezagitamab, TAK-079 | Takeda | Kidney Disease, Glomerulonephritis | 03/26 | 03/26 | | |
| Available | N/A | | NA | Pegcetacoplan | Apellis Pharmaceuticals, Inc. | C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | | | | |
NCT04971590: Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis |
|
|
| Recruiting | N/A | 200 | RoW | Participant completed survey, Medical chart review | GlaxoSmithKline | Systemic Lupus Erythematosus | 08/24 | 08/24 | | |
| Recruiting | N/A | 210 | Europe | KidneYou APP | Advice Pharma Group srl | Chronic Kidney Diseases, Diabetes, Arterial Hypertension, Chronic Glomerulonephritis, Cystic Kidney Diseases, Polycystic Kidney, Nephronophthisis, Cortical Cystic Disease, Cystic Diseases, Tuberous Sclerosis, Albuminuria, Treatment Adherence, Treatment Adherence and Compliance | 06/24 | 06/24 | | |
NCT04522505: Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis |
|
|
| Active, not recruiting | N/A | 7 | RoW | | Corestemchemon, Inc., Hanyang University | Lupus Nephritis | 02/24 | 05/24 | | |
NCT06277427: Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells |
|
|
| Recruiting | N/A | 24 | RoW | PRG-1801 （CAR-T against BCMA） | Lingli Dong, Shenzhen Pregene Biopharma Co., Ltd. | Lupus Nephritis, ANCA Associated Vasculitis | 02/26 | 01/27 | | |
NCT06210464: Disease and Biomarker Profiling of Chinese Lupus Nephritis |
|
|
| Not yet recruiting | N/A | 100 | NA | | Nan Shen, Novartis | Characterize the Molecular Profile of Lupus Nephritis(LN) Patients to Understand Themechanism(s)Contributing to Patient Responsiveness to Soc, Integrated Analysis of LN Patient Molecular Profiling and Clinical Annotations to Understand LNdisease Heterogeneity for Disease Endotype, Validate the Association of the Candidate Biomarker Panel Proposed in Table 3-1 With LN Diseasemonitoring | 03/25 | 03/25 | | |
NCT06445127: Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging) |
|
|
| Recruiting | N/A | 15 | US | MRI | Johns Hopkins University, Janssen Scientific Affairs, LLC | Lupus Nephritis, Lupus Erythematosus, Systemic, Lupus, SLE, SLE Nephritis, SLE; Glomerulonephritis (Etiology), SLE (Systemic Lupus) | 05/26 | 05/26 | | |
NCT04534647: Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort |
|
|
| Recruiting | N/A | 100 | RoW | different serum and urine biomarkers, Transcriptome studies | Liga Panamericana de Asociaciones de Reumatologia (PANLAR), Janssen Research & Development, LLC | Lupus Nephritis | 06/24 | 06/25 | | |
NCT06217107: Wellness & Workforce Solution for Lupus/Lupus Nephritis |
|
|
| Not yet recruiting | N/A | 160 | NA | Micro-learning content, Health360x app, Culturally congruent coaching | Morehouse School of Medicine, Janssen Scientific Affairs, LLC | Lupus Nephritis | 11/24 | 11/24 | | |
NCT04645589: Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis |
|
|
| Active, not recruiting | N/A | 72 | RoW | Myfortic, Mycophenolate sodium | Novartis Pharmaceuticals | Lupus Nephritis | 07/25 | 07/25 | | |
| Not yet recruiting | N/A | 300 | NA | None (Observational study), Observational Study | GlaxoSmithKline | Lupus Nephritis | 03/29 | 03/29 | | |
SAN-BB-01, NCT01931644: At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions |
|
|
| Completed | N/A | 17667 | US | | Sanguine Biosciences | All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis | 04/24 | 04/24 | | |
NCT05337124: A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US |
|
|
| Recruiting | N/A | 300 | US | LUPKYNIS, voclosporin | Aurinia Pharmaceuticals Inc., United BioSource, LLC | Lupus Nephritis | 11/26 | 06/30 | | |